Table 2 Change of the solvent-accessible surface area (ΔSASA) of the RMFPNAPYL peptide in the absence of the ESK1 Fab (calculated from the X-ray crystal structure with PDB ID 4WUU) and comparison to the confirmed cross-reactive peptides, ordered by their signal in the JNFAT activation assay
From: The physiological interactome of TCR-like antibody therapeutics in human tissues
Position | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 |
---|---|---|---|---|---|---|---|---|---|
WT1126-134 | R | M | F | P | N | A | P | Y | L |
ΔSASA without ESK1 | 69.1 | 0.0 | 0.0 | 35.7 | 15.1 | 0.0 | 0.0 | 0.0 | 0.0 |
Interacts with ESK1 | ✔ | ⨯ | ⨯ | (✔) | ⨯ | ⨯ | ⨯ | ⨯ | ⨯ |
SHC1469-477 | R | V | P | P | P | P | Q | S | V |
ARHGEF26863-871 | R | L | L | G | L | E | T | N | V |
RBM4B59-67 | K | L | H | G | V | N | I | N | V |
USP9Y1674-1682 | R | L | W | G | E | P | V | N | L |
CYP2C859-67 | K | V | Y | G | P | V | F | T | V |
CRYL1130-138 | K | L | F | A | G | L | V | H | V |
SF3B478-86 | K | L | Y | G | K | P | I | R | V |
ILF2127-135 | K | I | L | P | T | L | E | A | V |